Edition:
India

Tigenix NV (G9U.BR)

G9U.BR on Brussels Stock Exchange

1.72EUR
17 Jan 2018
Change (% chg)

€-0.00 (-0.23%)
Prev Close
€1.72
Open
€1.72
Day's High
€1.72
Day's Low
€1.72
Volume
2,025,470
Avg. Vol
2,222,149
52-wk High
€1.73
52-wk Low
€0.68

Select another date:

Fri, Jan 5 2018

Japan's Takeda to acquire TiGenix for $630 mln

TOKYO, Jan 5 Japan's Takeda Pharmaceutical Co said on Friday it has agreed to buy Belgian biotech group TiGenix NV for 520 million euros ($628 million).

BRIEF-Tigenix Confirms Strategic Focus On Cx601 And Its Adipose Derived Stem Cell Platform

* CONFIRMS STRATEGIC FOCUS ON CX601 AND ITS ADIPOSE DERIVED STEM CELL (EASC) PLATFORM Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Tigenix Plans To Focus On Its eASC Platform And Product Candidates Cx601 And Cx611

* TIGENIX NV SAYS PLANS TO FOCUS ITS RESOURCES AND CAPABILITIES ON ITS EASC PLATFORM TECHNOLOGY AND ITS PRODUCT CANDIDATES CX601 AND CX611 Source text for Eikon: Further company coverage:

BRIEF-Takeda And Tigenix Announces That CX601 Has Received a Positive CHMP Opinion

* REG-TAKEDA AND TIGENIX ANNOUNCE THAT CX601 (DARVADSTROCEL) HAS RECEIVED A POSITIVE CHMP OPINION TO TREAT COMPLEX PERIANAL FISTULAS IN CROHN'S DISEASE

BRIEF-Tigenix Nv - Mesoblast Grants Access To Patents To Support Commercialization Of Adipose-Derived Mesenchymal Stem Cell Product Cx601 For Treatment Of Fistulae​

* - MESOBLAST GRANTS ACCESS TO PATENTS TO SUPPORT COMMERCIALIZATION OF ADIPOSE-DERIVED MESENCHYMAL STEM CELL PRODUCT CX601 FOR TREATMENT OF FISTULAE​

BRIEF-JP Morgan Chase & Co notifies 3.12 pct shareholding in Tigenix​

* ‍JP Morgan Chase & Co notifies 3.12 pct shareholding in Tigenix​ Source text for Eikon: Further company coverage:

BRIEF-Tigenix announces approval of trade name for CX601 in Europe

* TIGENIX ANNOUNCES APPROVAL OF TRADE NAME FOR LEAD DEVELOPMENT CANDIDATE CX601 IN EUROPE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Tigenix announces partial conversion of bonds

* ‍ANNOUNCES CONVERSION OF EUR 7 MILLION OF COMPANY'S SENIOR UNSECURED CONVERTIBLE BONDS DUE 2018​

BRIEF-Tigenix obtains patent for Cx601 lead development program

* REG-TIGENIX STRENGTHENS EUROPEAN IP PROTECTION AROUND LEAD DEVELOPMENT PROGRAM CX601

BRIEF-TiGenix provides update on Cx601 marketing authorization application

* REG-TIGENIX PROVIDES REGULATORY UPDATE ON CX601 EU MARKETING AUTHORIZATION APPLICATION PROCEDURE

Select another date: